Abstract:【Abstract】Objective To explore the efficacy of entecavir in the treatment of decompensated hepatitis B cirrhosis and its effects on levels of plasma connective tissue growth factor (CTGF) and plateletderived growth factor (PDGF). Methods The clinical data of 238 patients with decompensated hepatitis B cirrhosis in our hospital were retrospectively analyzed. According to the treatment methods, they were divided into lamivudine+ adefovir dipivoxil treatment group (control group, 109 cases) and entecavir treatment group (observation group, 129 cases). The negative conversion rate of hepatitis B virus desoxyribonucleic acid (HBV DNA), reversion rate of alanine aminotransferase (ALT), drug resistance rate and occurrence of adverse reactions during treatment were recorded in the two groups at 24 weeks and 48 weeks of treatment, and the liver function (Child Pugh score), liver fibrosis degree ［transient elasticity test for liver stiffness measure (LSM), ultrasound quantitative score］ and serological indicators (CTGF, PDGF) were compared between the two groups before treatment and after 48 weeks of treatment. Results At 24 weeks and 48 weeks of treatment, the HBV DNA negative conversion rate and ALT reversion rate in observation group were higher than those in control group (P＜005). There were no significant differences in the drug resistance rate and occurrence of adverse reactions between the two groups during treatment (P＞005). After 48 weeks of treatment, the Child Pugh score, liver fibrosis degree (LSM, ultrasound quantitative score) and serological indicators (CTGF, PDGF) in the two groups were lower than those before treatment (P＜005), and the indexes in observation group were lower than those in control group (P＜005). Conclusion Entecavir has better effects and better antiviral effect than lamivudine+adefovir dipivoxil in the treatment of decompensated hepatitis B cirrhosis, and it can improve the liver function and liver fibrosis of patients, and it has high safety and high clinical application value.
